



A




Number of substitutions

B



Number of double-substitutions

C




Number of indels

D

Formaldehyde (120 µM)	0.3		1
MNU (350 µM)	1.2		
ENU (400 µM)	6		
DMS (0.078 mM)	1		
1,2-DMH (11.6 mM) + S9	6.2	7.1	1.4
DES (0.938 mM)	1.9		
Temozolomide (200 µM)	1.8		1.1
Semustine (150 µM)	0.3		
Mechlorethamine (0.3 µM)	0.4		
Ellipticine (0.25 µM)			1.3
Ellipticine (0.625 µM) + S9			1
Ellipticine (0.125 µM)			0.9
Ellipticine (0.375 µM) + S9	1		1.1
Cyclophosphamide (18.75 µM) + S9	0.4		
Cisplatin (12.5 µM)	2.8	43	3.5
Cisplatin (3.125 µM)	0.6	11.6	1
Carboplatin (5 µM)	0.6	8.9	0.7
AZD7762 (1.625 µM)	0.5		
Benzidine (200 µM)	1.2		1.1
4-ABP (300 µM) + S9	0.6		
PhIP (4 µM) + S9	2		1.3
PhIP (3 µM) + S9	0.9		0.7
SSR (1.25 J)	6.9	66.3	0.9
Gamma irradiation (2 Gray)			1.3
N-Nitrosopyrrolidine (50 mM)	0.4		
DBPDE (0.000625 µM)	2.6		1.3
DBPDE (0.000156 µM)	0.9		0.7
DBP (0.0313 µM) + S9	1.2		1
DBP (0.0039 µM)	0.3		
DBADE (0.0313 µM)	6.1	8.4	3.5
DBADE (0.109 µM)	15.3	20.1	7.8
DBAC (5 µM) + S9	0.7		
DBA (75 µM) + S9	4.6	8.9	1.9
BPDE (0.125 µM)	12.1	25.5	16
BaP (2 µM) + S9	2.2	5.3	3.5
BaP (0.39 µM) + S9	1.5	3.9	1.6
5-Methylchrysene (1.6 µM) + S9	4.9	3.9	1.2
6-Nitrochrysene (50 µM)	9.1	5.1	2.2
6-Nitrochrysene (50 µM) + S9	8.8	3.7	2.5
6-Nitrochrysene (0.78 µM)	5	3.5	0.8
6-Nitrochrysene (12.5 µM) + S9	1.3		0.9
3-NBA (0.1 µM)	3.3		2.9
3-NBA (0.025 µM)	1.1		0.7
1,8-DNP (0.125 µM)	4.6	7.5	7.3
1,6-DNP (0.09 µM)	1.3		2.3
1,6-DNP (0.09 µM)	0.6		1.2
Potassium bromate (260 µM)	0.9		0.9
Potassium bromate (875 µM)	1.3		1.4
Cobalt (II) chloride (250 µM)			0.8
Propylene oxide (10 mM)	2.4		
OTA (0.08 µM) + S9	0.4		0.8
MX (7 µM) + S9	1.6		1.4
Methyleugenol (1.25 mM)	0.4		0.9
Furan (100 mM) + S9	0.4		
AFB1 (0.25 µM) + S9	0.5		
AAII (37.5 µM)	0.4		
AAI (1.25 µM)	3.8		1

Sub. Dsub. Indel
Mutation type



Mutagenicity
index

** $Q \leq 0.01$

*** $Q \leq 0.001$